updated 11/15/2010 9:46:01 AM ET 2010-11-15T14:46:01

CHICAGO, Nov. 15, 2010 (GLOBE NEWSWIRE) -- Errant Gene Therapeutics, LLC (EGT), a biopharmaceutical company headquartered in Chicago, Illinois, announced that it has been awarded a $245,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program.

The QTDP, created by U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010, is designed to promote medical research that could improve health and save lives.

"We are extremely pleased that our Thalagen™ project has been reviewed and assessed positively by the federal government, resulting in a grant at the maximum level available under the QTDP grant program," said Pat Girondi, EGT's Chief Executive Officer. "These funds and other sources continue to help support EGT's ongoing research and development programs."

EGT said it will use the grant to further advance its international clinical programs for Thalagen, for which it has already secured designation as an Orphan Drug in both the US and European for chronic beta Thalassemias (also called Cooley's Anemia). Thalagen is an applied regenerative therapy that seeks to permanently end transfusion dependence for patients, essentially curing this disease. Thalassemia, a deadly genetic condition, is one of the world's largest hereditary blood disorders. The company said it plans to launch the US Phase 1 human clinical trials of Thalagen in Q1 2011.

The QTDP was intended specifically to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries that show potential to produce new therapies that address areas of unmet medical need, and reduce long-term health care costs. In addition, awards took into consideration research that demonstrates the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences.

About Errant Gene Therapeutics, LLC

Errant Gene Therapeutics™ (EGT) is a privately held biopharmaceutical company established in 2003. The Company's Applied Genetics Platform, include intellectual property, know-how and licenses being developed to directly target deadly hereditary disorders, including chronic beta thalassemia and hemoglobinopathies. In addition, EGT is a pioneer in the field of epigenetics, where its patents and know-how are being developed to enable the treatment of deadly hormone refractory cancers using its portfolio of small molecule histone deacetylases inhibitors.

For more information about Errant Gene Therapeutics and its programs, visit www.errantgene.com . You can also call:

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com